Intralesional measles, mumps, rubella (MMR) vaccine versus tuberculin purified protein derivative (PPD) in the treatment of palmoplantar and periungual warts: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200604014

Enrollment

Registered

2020-06-04

Start date

2020-06-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clearance of warts warts , tuberculin purified protein derivative (PPD), measles, mumps, rubella (MMR) vaccine , intralesional

Interventions

Patients randomly assigned to treat palmoplantar and periungual warts will receive 0.3 ml MMR vaccine at 2-week intervals until complete clearance is achieved or for a maximum of 5 treatment sessions

Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine

Intralesional measles, mumps, rubella (MMR) vaccine ,Intralesional tuberculin purified protein derivative (PPD)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least one palmoplantar or periungual wart. Personal history of MMR vaccine

Exclusion criteria

Exclusion criteria: History of topical treatment of target wart within 2 weeks or other treatment target warts within 4 weeks prior to our study Have fever or other inflammation or infection in any part of body Immunocompromised host, using immunosuppressive drugs, or current radiotherapy Receiving immunoglobulin within 6 weeks pregnant or lactating women currently using anticoagulant drugs Personal history of asthma, severe dermatitis, meningitis, TB, epilepsy

Design outcomes

Primary

Measure	Time frame
Complete remission of target wart lesion 6 months after final treatment Clinical evaluation by a blind evaluator	—

Secondary

Measure	Time frame
Complete remission of distant wart lesion 6 months after final treatment Clinical evaluation by a blind evaluator ,Treatment response by area changes of target wart Every visit Area of target wart/ Image J software,Treatment response by area changes of distant wart Every visit Area of target wart/ Image J software,Treatment response by clinical improvement of target wart Every visit Improvement percentages/ clinical assessment ,Treatment response by clinical improvement of distant wart Every visit Improvement percentages/ clinical assessment ,Characteristics of target wart First visit Dermoscope ,Characteristics of distant wart First visit Dermoscope ,Pain score Every treatment session Visual analog scale ,Recurrence 6 months after final treatment The development of a wart in a treated area	—

Measure

Time frame

Complete remission of distant wart lesion 6 months after final treatment Clinical evaluation by a blind evaluator ,Treatment response by area changes of target wart Every visit Area of target wart/ Image J software,Treatment response by area changes of distant wart Every visit Area of target wart/ Image J software,Treatment response by clinical improvement of target wart Every visit Improvement percentages/ clinical assessment ,Treatment response by clinical improvement of distant wart Every visit Improvement percentages/ clinical assessment ,Characteristics of target wart First visit Dermoscope ,Characteristics of distant wart First visit Dermoscope ,Pain score Every treatment session Visual analog scale ,Recurrence 6 months after final treatment The development of a wart in a treated area

—

Countries

Thailand

Contacts

Public ContactSuthinee Rutnin

Faculty of Medicine, Ramathibodi hospital

suthinee.rutnin@gmail.com022011211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026